|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Patient Compliance in Psychiatry - From Patient Acquisition to Patient Retention
Datamonitor, Dec 2004, Pages: 188
Introduction
Generic saturation coupled with a poor R&D pipeline is forcing pharmaceutical companies to seek alternative ways of maintaining revenue growth in the ever-competitive psychiatry sector. Surprisingly, despite being long recognized as a costly problem, interest in patient compliance is only just gaining momentum and effective patient compliance programs have yet to become standard practice.
Scope
Analysis of the prevalence of noncompliance in schizophrenia, bipolar disorder and depression with an overview of compliance improving strategies
For these three disorders: discussion of general and side-effect specific reasons for noncompliance
Insight into the actions taken by care managers of noncompliant patients
In-depth analysis of the perceived usefulness of approaches to tackle noncompliance and the influence of education sources
Highlights
Players in the schizophrenia, bipolar disorder, and depression markets lose millions of dollars in drug sales annually due to noncompliance. Capturing this lost revenue is becoming ever important as the return on investment of traditional lifecycle management strategies is dwindling.
Pfizer and Eli Lilly have both implemented large compliance programs in psychiatry, which have been well received by the medical community. The popularity of these programs can be attributed to a patient-focused design, which, among other benefits, has served the companies profile among end-users.
Ultimately, education to patients is a free service provided by companies. If shown to improve treatment outcomes in controlled studies, companies would be in a stronger position to convince payers and regulatory bodies to advocate their brands over generics.
Reasons to Purchase
Understand the key reasons causing noncompliance in schizophrenia, bipolar disorder, and depression and the actions taken by therapists
Benchmark your own patient compliance programs to those that have already been conducted by other companies
Optimize the communication of your compliance messages by recognizing the most influential sources of information for these patient groups
Customers who bought this item also bought
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians’ Favorite
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Stakeholder Insight: Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth
Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding Market
Stakeholder Insight: Inflammatory Bowel Disease - Efficacy and Compliance Key to Maximizing Patient Share as Novel Biologics Wait in the Wings
Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
Treatment-resistant depression: An untapped area of the patient population
The 2009 World Forecasts of Butadiene Rubber (BR) Export Supplies
The 2009 Import and Export Market for Butadiene Rubber (BR) in France
The 2009 Import and Export Market for Butadiene Rubber (BR) in Germany
|
|
|
|
